COMP <GO>
ANIP vs KLRA // FREE CASH FLOW YIELD
ANI Pharmaceuticals Inc. (NASDAQ) VS. Kailera Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ANIP 1
— KLRA 2
■ METRIC PARITY
LAST: $70.67 (-1.85%) • MKT CAP: $1.65B
fcf-yield
10.20%
LAST: $12.15 (-5.52%) • MKT CAP: $1.67B
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIP VS. KLRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIP | KLRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 10.20% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 12.60% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 8.80% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 43.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.07% | 0.00% | +0.07 | ANIP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 51.7 | -4.40 | KLRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.1x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.65B | $1.67B | -$14.1M | KLRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIP REV | KLRA REV | ANIP GROSS % | KLRA GROSS % | ANIP FCF | KLRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $883.4M | $290.8M | — | — | $171.4M | — |
| FY 2024 | $614.4M | — | — | — | $47.8M | — |
| FY 2023 | $486.8M | — | — | — | $119.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIP // BETA —
KLRA // BETA —